Catherine M. Lockhart, PharmD, PhD

Executive Director
Biologics and Biosimilars Collective Intelligence Consortium

Poster(s):

• (52) Impact of Medication Adherence on Clinical and Economic Outcomes in Multiple Sclerosis: A Scoping Review of Real-World Evidence
  Wednesday, October 29, 2025

• (183) Impact of COVID-19 on non-COVID related treatment patterns and outcomes in patients with inflammatory bowel disease (IBD)
  Wednesday, October 29, 2025

• (195) Methods for imputing race and ethnicity in real-world data: a scoping review
  Wednesday, October 29, 2025

• (344) Disruption and adaptation in inflammatory bowel disease: Impact of the COVID-19 pandemic on treatment patterns, healthcare utilization, and vaccination in the United States
  Wednesday, October 29, 2025